Reverse remodelling by sacubitril/valsartan predicts the prognosis in heart failure with reduced ejection fraction

AIMS: Despite well‐established benefits of sacubitril/valsartan for cardiac reverse remodelling and the prognosis of patients with heart failure with reduced ejection fraction (HFrEF), there are some patients with limited therapeutic response, even with optimal therapy. We assessed the treatment res...

Descripción completa

Detalles Bibliográficos
Autores principales: Moon, Mi‐Gil, Hwang, In‐Chang, Choi, Wonsuk, Cho, Goo‐Yeong, Yoon, Yeonyee E., Park, Jun‐Bean, Lee, Seung‐Pyo, Kim, Hyung‐Kwan, Kim, Yong‐Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8120366/
https://www.ncbi.nlm.nih.gov/pubmed/33682334
http://dx.doi.org/10.1002/ehf2.13285

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8120366/
https://www.ncbi.nlm.nih.gov/pubmed/33682334
http://dx.doi.org/10.1002/ehf2.13285

Ejemplares similares